Accreditation Information

To request a Grand Rounds, please click here.

 

ACCREDITATION

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Medicine (ACCME)

CEC designates this live educational activity for a maximum of 1.0 (AMA PRA Category 1 Credit)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacy (ACPE)
This application-based activity is approved for 1.0 contact hour (.10 CEUs) of continuing pharmacy education credit (JA0007101-0000-18-001-L01-P).

Nursing (ANCC)
This activity is designated for 1.0 contact hour.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Upon completion of a CE request form, statements of credit for physicians and nurses will be issued within 30 business days. Pharmacy credit will be reported directly to the National Association of Boards of Pharmacy® (NABP®) CPE Monitor electronic CE tracking system.

Needs Statement

Bruton’s tyrosine kinase (BTK) inhibitors are in a new class of targeted therapies that is revolutionizing the treatment of many forms of cancer, including B-cell lymphomas—the most common type of hematologic malignancy. A first-generation BTK inhibitor already has dramatically changed the treatment calculus in B-cell cancers, and now second-generation agents are available that may offer advantages in safety while also delivering high rates of response. Such therapies will play an increasingly important role in the management of B-cell malignancies, and as an alternative to highly toxic chemotherapy.

BTK inhibitor therapy’s much greater tolerability over other treatment options allows for treatment over a long period of time and for treatment to occur outside the confines of the clinic. In this situation, patient education and engagement are increasingly important factors in treatment success. Shared decision making (SDM)—practitioners and patients actively working together to formulate treatment plans that take into account patient preferences and concerns—is an invaluable component of engaging patients in their own care and improving their adherence to therapy.

This Grand Rounds program will provide attendees with an understanding of the role of BTK inhibitors within the spectrum of pharmacologic therapy for B-cell lymphomas and will offer insights into principles of SDM and related approaches to better engage patients as partners in care, with the goal of improving outcomes over the long term.

Objectives

1. Analyze the changing paradigm in clinical approaches to management of B-cell malignancies with BTK therapy and the implications for patient care.
2. Evaluate the respective safety and efficacy profiles of first- vs. second-generation BTK inhibitors.
3. Effectively incorporate BTK inhibitors into chronic management of B-cell malignancies.
4. Examine effective team-based strategies to improve patient adherence to oral chemotherapy. 

Target Audience

Practitioners involved in the care of patients with B-cell malignancies, including oncologists, hematologists, oncology/hematology residents/fellows, oncology specialty nurse practitioners, nurses, nurse navigators, physician assistants, and pharmacists.

Faculty Disclosure

PLANNER AND FACULTY DISCLOSURES

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as an entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

 

PLANNERS
Vanessa Carranza, PharmD has no relevant financial relationships to disclose in relation to the content of this activity.

Mollie E. Moran, MSN, CNP, AOCNP® has no relevant financial relationships to disclose in relation to the content of this activity.

Susan H. Scher, MD has no relevant financial relationships to disclose in relation to the content of this activity.

Jennifer A. Woyach, MD has disclosed that she receives grant/research support from Abbvie, Karyopharm,and Morphosys.

 

PRESENTERS
John N. Allan, MD-has disclosed that he is a consultant for Abbvie, Genentech, Pharmacyclics, and Verastem.

Danielle M. Brander, MD-has disclosed that she is a consultant for Abbvie, Genentech, Pharmacyclics, T6 Therapeutics, and Teva. She receives other financial/material support from the Novartis.

Matthew S. Davids, MD, MMSc-has disclosed that he is a consultant for Abbvie, AstraZeneca, Celgene, Genentech, Janssen, Merck, MEI Pharma, and Pharmacyclics. He also receives grant/research support from Bristol-Myers Squibb, Genentech, Pharmacyclics, Surface Oncology, and TG Therapeutics.

Brian T. Hill, MD, PhD- has disclosed that he receives grant/research support from Abbvie and Pharmacyclics.

Javier Pinilla-Ibarz, MD, PhD-has disclosed that he is a consultant for Abbvie, Gilead, Janssen, Novartis, Pfizer, and Pharmacyclics. He also is a member of the speakers’ bureaus for Abbvie, Gilead, and Pharmacyclics.

Nina Wagner-Johnston, MD-has disclosed that she is a consultant for ADC Therapeutics, Janssen, and Juno.

Loretta J. Nastoupil, MD-has disclosed that she is a consultant for Celgene, Genentech, Gilead, and Merck.

Kerry A. Rogers, MD-has disclosed that she receives grant/research support from Genentech.

Stephen E. Spurgeon, MD-has disclosed that he is a consultant for Gilead and Pharmacyclics. He also receives grant/research support Acerta, AstraZeneca, Bristol-Myers Squibb, and Genentech.

Jennifer A. Woyach, MD-has disclosed that she receives grant/research support from Abbvie, Karyopharm, and MorphoSys.